TY - JOUR
T1 - Advances in treatment of mesothelioma
AU - Maggioni, C.
AU - Barletta, G.
AU - Rijavec, E.
AU - Biello, F.
AU - Gualco, E.
AU - Grossi, F.
PY - 2016/4/22
Y1 - 2016/4/22
N2 - Introduction: Malignant pleural mesothelioma (MPM) is an uncommon, aggressive cancer, derived from pleural mesothelial cells, that has a close relationship to asbestos exposure. To date, MPM prognosis is poor and very few treatment options are available for both localized and advanced MPM. Areas covered: The standard of care is still chemotherapy with platinum derivates and antifolate agents. In the last few years, several new agents have been studied on the basis of mesothelioma carcinogenesis and invasiveness mechanisms; however, the recent results are poor and few drugs have been tested in phase III trials because of toxicity or because they did not improve patient outcomes. The aim of this review is to focus on the current available treatment for MPM through the analysis of the results comes from the phase III trials and to discuss the future perspectives in the pathogenesis, diagnosis and treatment. Expert Opinion: Many compounds are currently under investigation in different subsets of patients. Interesting data have come from preliminary studies on immunotherapy, but randomized studies are needed to confirm the preliminary positive results of this new strategy. A better comprehension of MPM pathogenesis should be obtained to improve and develop new diagnostic tools and target therapies.
AB - Introduction: Malignant pleural mesothelioma (MPM) is an uncommon, aggressive cancer, derived from pleural mesothelial cells, that has a close relationship to asbestos exposure. To date, MPM prognosis is poor and very few treatment options are available for both localized and advanced MPM. Areas covered: The standard of care is still chemotherapy with platinum derivates and antifolate agents. In the last few years, several new agents have been studied on the basis of mesothelioma carcinogenesis and invasiveness mechanisms; however, the recent results are poor and few drugs have been tested in phase III trials because of toxicity or because they did not improve patient outcomes. The aim of this review is to focus on the current available treatment for MPM through the analysis of the results comes from the phase III trials and to discuss the future perspectives in the pathogenesis, diagnosis and treatment. Expert Opinion: Many compounds are currently under investigation in different subsets of patients. Interesting data have come from preliminary studies on immunotherapy, but randomized studies are needed to confirm the preliminary positive results of this new strategy. A better comprehension of MPM pathogenesis should be obtained to improve and develop new diagnostic tools and target therapies.
KW - chemotherapy
KW - clinical trials
KW - immunotherapy
KW - Malignant pleural mesothelioma
UR - http://www.scopus.com/inward/record.url?scp=84964434855&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84964434855&partnerID=8YFLogxK
U2 - 10.1080/14656566.2016.1176145
DO - 10.1080/14656566.2016.1176145
M3 - Article
AN - SCOPUS:84964434855
SP - 1
EP - 9
JO - Expert Opinion on Pharmacotherapy
JF - Expert Opinion on Pharmacotherapy
SN - 1465-6566
ER -